Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation.
- Author:
Chi Kyung KIM
1
;
Seunguk JUNG
;
Byung Woo YOON
Author Information
1. Department of Neurology, and Clinical Research Center for Stroke, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea. bwyoon@snu.ac.kr
- Publication Type:Review
- Keywords:
Cardioembolic stroke;
Atrial fibrillation;
CHADS2;
New oral anticoagulants;
Prevention;
Review
- MeSH:
Aging;
Anticoagulants;
Atrial Fibrillation;
Prognosis;
Recurrence;
Stroke;
Warfarin
- From:Journal of Stroke
2013;15(3):144-152
- CountryRepublic of Korea
- Language:English
-
Abstract:
Stroke associated with non-valvular atrial fibrillation (NVAF) is one of the most important subtypes of ischemic stroke, and its importance is becoming even more apparent in an aging population. To assess the risk of stroke associated with NVAF, the CHADS2 and CHA2DS2-VASc scores are mainly used. Such scores can be used to predict the recurrence and prognosis of ischemic stroke. In addition, new oral anticoagulants (NOACs) and devices are being evaluated in the prevention of stroke associated with NVAF in addition to treatment with the conventional oral anticoagulant, warfarin. Since clinical experience with NOACs is not globally sufficient, a cautious approach is needed.
